These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18640574)

  • 1. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.
    Smith SM; van Besien K; Carreras J; Bashey A; Cairo MS; Freytes CO; Gale RP; Hale GA; Hayes-Lattin B; Holmberg LA; Keating A; Maziarz RT; McCarthy PL; Navarro WH; Pavlovsky S; Schouten HC; Seftel M; Wiernik PH; Vose JM; Lazarus HM; Hari P
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):904-12. PubMed ID: 18640574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse.
    Kharfan-Dabaja MA; Labopin M; Polge E; Nishihori T; Bazarbachi A; Finke J; Stadler M; Ehninger G; Lioure B; Schaap N; Afanasyev B; Yeshurun M; Isaksson C; Maertens J; Chalandon Y; Schmid C; Nagler A; Mohty M
    JAMA Oncol; 2018 Sep; 4(9):1245-1253. PubMed ID: 30003233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Devetten MP; Hari PN; Carreras J; Logan BR; van Besien K; Bredeson CN; Freytes CO; Gale RP; Gibson J; Giralt SA; Goldstein SC; Gupta V; Marks DI; Maziarz RT; Vose JM; Lazarus HM; Anderlini P
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):109-17. PubMed ID: 19135949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia.
    Yalniz FF; Saliba RM; Greenbaum U; Ramdial J; Popat U; Oran B; Alousi A; Olson A; Alatrash G; Marin D; Rezvani K; Hosing C; Im J; Mehta R; Qazilbash M; Joseph JJ; Rondon G; Kanagal-Shamanna R; Shpall E; Champlin R; Kebriaei P
    Transplant Cell Ther; 2021 Aug; 27(8):689-695. PubMed ID: 34023569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.
    Freytes CO; Zhang MJ; Carreras J; Burns LJ; Gale RP; Isola L; Perales MA; Seftel M; Vose JM; Miller AM; Gibson J; Gross TG; Rowlings PA; Inwards DJ; Pavlovsky S; Martino R; Marks DI; Hale GA; Smith SM; Schouten HC; Slavin S; Klumpp TR; Lazarus HM; van Besien K; Hari PN
    Biol Blood Marrow Transplant; 2012 Aug; 18(8):1255-64. PubMed ID: 22198543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
    Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.
    Ram R; Gooley TA; Maloney DG; Press OW; Pagel JM; Petersdorf SH; Shustov AR; Flowers ME; O'Donnell P; Sandmaier BM; Storb RF; Gopal AK
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1537-45. PubMed ID: 21536145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
    Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
    Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
    Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
    Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Dholaria B; Finke J; Brecht A; Schanz U; Niittyvuopio R; Neubauer A; Bornhäuser M; Santarone S; Beelen D; Shimoni A; Rösler W; Giebel S; Savani BN; Mohty M
    Br J Haematol; 2019 Sep; 186(5):767-776. PubMed ID: 31115916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Majolino I; Pearce R; Taghipour G; Goldstone AH
    J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
    Sibon D; Morschhauser F; Resche-Rigon M; Ghez D; Dupuis J; Marçais A; Deau-Fischer B; Bouabdallah R; Sebban C; Salles G; Brice P
    Haematologica; 2016 Apr; 101(4):474-81. PubMed ID: 26721893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry.
    Freytes CO; Loberiza FR; Rizzo JD; Bashey A; Bredeson CN; Cairo MS; Gale RP; Horowitz MM; Klumpp TR; Martino R; McCarthy PL; Molina A; Pavlovsky S; Pecora AL; Serna DS; Tsai T; Zhang MJ; Vose JM; Lazarus HM; van Besien K;
    Blood; 2004 Dec; 104(12):3797-803. PubMed ID: 15280203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second autologous transplant with cyclosporin/interferon alpha-induced graft versus host disease for patients who have failed first-line consolidation.
    Streetly M; Kazmi M; Radia D; Hoyle C; Schey SA
    Bone Marrow Transplant; 2004 Jun; 33(11):1131-5. PubMed ID: 15094743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma.
    Majhail NS; Bajorunaite R; Lazarus HM; Wang Z; Klein JP; Zhang MJ; Rizzo JD
    Br J Haematol; 2009 Oct; 147(1):129-39. PubMed ID: 19573079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.
    Rezvani AR; Kanate AS; Efron B; Chhabra S; Kohrt HE; Shizuru JA; Laport GG; Miklos DB; Benjamin JE; Johnston LJ; Arai S; Weng WK; Negrin RS; Strober S; Lowsky R
    Bone Marrow Transplant; 2015 Oct; 50(10):1286-92. PubMed ID: 26146806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of pediatric patients with lymphoma following stem cell transplant: a single institution report.
    Sumaili H; Al-Kofide A; Al-Seraihi A; Ayas M; Siddiqui K; El-Solh H; Al-Jefri A; Al-Ahmari A; Mohamed A; Anas M; Belgaumi AF
    Leuk Lymphoma; 2015 May; 56(5):1327-34. PubMed ID: 25139691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.
    Giulino-Roth L; Ricafort R; Kernan NA; Small TN; Trippett TM; Steinherz PG; Prockop SE; Scaradavou A; Chiu M; O'Reilly RJ; Boulad F
    Pediatr Blood Cancer; 2013 Dec; 60(12):2018-24. PubMed ID: 24038967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.
    Bhatia R; Van Heijzen K; Palmer A; Komiya A; Slovak ML; Chang KL; Fung H; Krishnan A; Molina A; Nademanee A; O'Donnell M; Popplewell L; Rodriguez R; Forman SJ; Bhatia S
    J Clin Oncol; 2005 Sep; 23(27):6699-711. PubMed ID: 16170178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.